3′-azido-3′-deoxythymidine induces deletions in L5178Y mouse lymphoma cells

Environmental and Molecular Mutagenesis

Volumn 48, Issue 3-4, 2007, Pages 248-257

  Wang, Jianyong ^a,b   Chen, Tao ^b   Honma, Masamitsu ^c   Chen, Ling ^b,d   Moore, Martha M ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

3 azido 3 deoxythymidine; Copy number; Loss of heterozygosity; Mouse lymphoma assay; Mutation spectrum

Indexed keywords

ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; CHROMOSOME 11; CONTROLLED STUDY; DELETION MUTANT; DOSE RESPONSE; GENE DELETION; GENE DOSAGE; GENE LOCUS; GENETIC RECOMBINATION; HETEROZYGOSITY LOSS; INDUCED MUTATION; LEUKEMIA L 5178 Y; LYMPHOMA CELL LINE; MICROSATELLITE MARKER; MOUSE; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; TK GENE; ANIMAL; DRUG EFFECT; GENETICS; TUMOR CELL LINE;

ANIMALS; ANTI-HIV AGENTS; CELL LINE, TUMOR; LOSS OF HETEROZYGOSITY; MICE; REVERSE TRANSCRIPTASE INHIBITORS; THYMIDINE KINASE; ZIDOVUDINE;

EID: 34047217354     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20263     Document Type: Article

References (58)

1. Adams WT, Skopek TR. 1987. Statistical test for the comparison of samples from mutational spectra. J Mol Biol 194:391-396.
2. Agarwal RP, Olivero OA. 1997. Genotoxicity and mitochondria damage in human lymphocytic cells chronically exposed to 3′-azido-3′- dideoxythymidine. Mutat Res 390:223-231.
3. Applegate ML, Moore MM, Broder CB, Burrell A, Juhn G, Kasweck KL, Lin PF, Wadhams A. Hozier JC. 1990. Molecular dissection of mutations at the heterozygous thymidine kinase locus in mouse lymphoma cells. Proc Natl Acad Sci USA 87:51-55.
4. Ayers KM, Clive D, Tucker WE, Hajian G, Miranda PD. 1996. Nonclinical toxicology studies with zidovudine: Genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam Appl Toxicol 32:148-158.
5. Ayers KM, Torrey CE, Reynolds DJ. 1997. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fundam Appl Toxicol 38:195-198.
6. Blazak WF, Los FJ, Rudd CJ, Caspary WJ. 1989. Chromosome analysis of small and large L5178Y mouse lymphoma cell colonies: Comparison of trifluorothymidine-resistant and unselected cell colonies from mutagen-treated and control cultures. Mutat Res 224:197-208.
7. Cariello NF. 1994. Software for the analysis of mutations at the human Hprt gene. Mutat Res 312:173-185.
8. Chen T, Moore MM. 2004. Screening for chemical mutagens using the mouse lymphoma assay. In: Yan Z, Caldwell GW, editors. Optimization in Drug Discovery: In-Vitro Methods. Totowa, NJ: Humana Press, pp 337-352.
9. -/- 3.7.2 C mouse lymphoma cells. Mutagen 13:427-434.
10. +/- mouse lymphoma cells. Mutagen 5:191-197.
11. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy JF, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J. 1994. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331:1173-1180.
12. Darnowski JW, Goulette FA. 1994. 3′-Azido-3′-deoxythymidine cytotoxicity and metabolism in the human colon tumor cell line HCT-8. Biochem Pharmacol 48:1797-1805.
13. Diwan BA, Riggs CW, Logsdon D, Haines DC, Olivero OA, Rice JM, Yuspa SH, Poirier MC, Anderson LM. 1999. Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-3′-deoxythymidine in mice. Toxicol Appl Pharmacol 161:82-99.
14. Gonzales-Cid M, Larripa I. 1994. Genotoxicity of azidothymidine (AZT) in in vitro systems. Mutat Res 321:113-118.
15. Helleday T. 2003. Pathways for mitotic homologous recombination in mammalian cells. Mutat Res 532:103-115.
16. Honma M. 2005. Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells. Environ Mol Mutagen 45:162-176.
17. Honma M, Zhang LS, Hayashi M, Takeshita K, Nakagawa Y, Tanaka N, Sofuni T. 1997. Illegitimate recombination leading to allelic loss and unbalanced translocation in p53-mutated human lymphoblastoid cells. Mol Cell Biol 17:4774-4781.
18. Honma M, Momose M, Tanabe H, Sakamoto H, Yu Y, Little JB, Sofuni T, Hayashi M. 2000. Requirement of wild-type p53 protein for maintenance of chromosomal integrity. Mol Carcinog 28:203-214.
19. Honma M, Momose M, Sakamoto H, Sofuni T, Hayashi M. 2001. Spindle poisons induce allelic loss in mouse lymphoma cells through mitotic non-disjunction. Mutat Res 493:101-114.
20. Honma M, Izumi M, Sakuraba M, Tadokoro S, Sakamoto H, Wang W, Yatagai F, Hayashi M. 2003. Deletion, rearrangement, and gene conversion; genetic consequences of chromosomal double-strand breaks in human cells. Environ Mol Mutagen 42:288-298.
21. -/- mouse lymphoma mutagenesis assay system. Mutat Res 84:169-181.
22. Jackson SP. 2002. Sensing and repairing DNA double-strand breaks. Carcinogenesis 23:687-696.
23. Joseph G, Grist S, Firgaira F, Turner D, Morley A. 1993. Classification of mutations at the HLA-A locus by use of the polymerase chain reaction. Environ Mol Mutagen 22:152-156.
24. Kennedy I, Williams S. 2000. Occupational exposure to HIV, post-exposure prophylaxis in healthcare workers. Occup Med 50:387-391.
25. Khanna KK, Jackson SP. 2001. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat Genet 27:247-254.
26. Lasko D, Cavenee W. 1991. Loss of constitutional heterozygosity in human cancer. Annu Rev Genet 25:281-314.
27. Liber HL, Yandell DW, Little JB. 1989. A comparison of mutation induction at the Tk and Hprt loci in human lymphoblastoid cells; quantitative differences are due to an additional class of mutations at the autosomal Tk locus. Mutat Res 216:9-17.
28. Liechty MC, Crosby H Jr, Murthy A, Davis LM, Caspary WJ, Hozier JC. 1996. Identification of a heteromorphic microsatellite within the thymidine kinase gene in L5178Y mouse lymphoma cells. Mutat Res 371:265-271.
29. Meng Q, Su T, Olivero OA, Poirier MC, Shi X, Ding X, Walker VE. 200Oa. Relationships between DNA incorporation, mutant frequency, and loss of heterozygosity at the TK locus in human lymphoblastoid cells exposed to 3′-Azido-3′-deoxythymidine. Toxicol Sci 54:322-329.
30. Meng Q, Grosovsky AJ, Shi X, Walker VE. 2000b. Mutagenicity and loss of heterozygosity at the APRT locus in human lymphoblastoid cells exposed to 3′-azido-3′-deoxythymidine. Mutagen 15:405-410.
31. Meng Q, Su T, O'Neill JP, Walker VE. 2002. Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3′-azido-3′-deoxythymidine and 2′,3′- dideoxyinosinedagger. Environ Mol Mutagen 39:282-295.
32. (-/-) mice treated as neonates with 3′-azido-3′- deoxythymidine (AZT). Mutat Res 547:63-69.
33. +/ mouse lymphoma cells. Mutat Res 151:161-174.
34. Moore MM, Harrington-Brock K, Doerr CL, Dearfield KL. 1989. Differential mutant quantitation at the mouse lymphoma Tk and CHO Hgprt loci. Mutagen 4:394-403.
35. Moore MM, Honma M, Clements J, Bolcsfoldi G, Burlinson B, Cifone M, Clarke J, Delongchamp R, Durward R, Fellows M, Gollapudi B, Hou S, Jenkinson P, Lloyd M, Majeska J, Myhr B, O'Donovan M, Omori T, Riach C, San R, Stankowski LF Jr, Thakur AK, Van Goethem F, Wakuri S, Yoshimura I. 2006. Mouse lymphoma thymidine kinase gene mutation assay: Follow-up meeting of the International Workshop on Genotoxicity Testing-Aberdeen, Scotland, 2003-Assay acceptance criteria, positive controls, and data evaluation. Environ Mol Mutagen 47:1-5.
36. NIH. 2004. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. Also available at http://aidsinfo.nih.gov/guidelines/
37. Olivero OA, Beland F A, Poirier MC. 1994. Immunofluroscent localization and quantitiation of 3′-azido-3′-deoxythymidine (AZT) incorporated into chromosomal DNA of human, hamster, and mouse cell lines. Int J Oncol 4:449-454.
38. Olivero OA, Anderson LM, Diwan BA, Haines DC, Harbaugh SW, Moskal TJ, Jones AB, Rice JM, Riggs CW, Logsdon D, Yuspa SH, Poirier MC. 1997. Transplancental effects of 3′-azido-2′,3′- dideoxythymidine(AZT): Tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 89:1602-1608.
39. Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Landay AL, Baker R, Stek AM, Khoury MM, Praia LA, Kessler HA, Sha BE, Tarone RE, Poirier MC. 1999. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS 13:919-925.
40. Pastink A, Eeken JC, Lohman PH. 2001. Genomic integrity and the repair of double-strand DNA breaks. Mutat Res 481:37-50.
41. Poirier MC, Patterson TA, Slikker W Jr, Olivero OA. 1999. Incorporation of 3′-azido-3′-deoxythymidine (AZT) into fetal DNA, fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. J Acquir Immune Defic Syndr 22:477-483.
42. Ponomareva ON, Rose JA, Lasarev M, Rasey J, Turker MS. 2002. Tissue-specific deletion and discontinuous loss of heterozygosity are signatures for the mutagenic effects of ionizing radiation in solid tissues. Cancer Res 62:1518-1523.
43. Rathmell WK, Chu G. 1998. Mechanisms for DNA double-strand break repair in eukaryotes. In: Nickoloff JA, Hoekstra MF, editors. DNA Damage and Repair, Vol. 2. Totowa, NJ: Humana press, pp. 299-316.
44. Sargent RG, Brenneman MA, Wilson JH. 1997. Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination. Mol Cell Biol 17:267-277.
45. +/- 3.7.2C mouse lymphoma cell line. Environ Mol Mutatgen 47:127-131.
46. +/ cell line is heterozygous for a codon 170 mutation in the p53 tumor suppressor gene. Mutat Res 373:157-165.
47. Sussman HE, Olivero OA, Meng Q, Pietras SM, Poirier MC, O'Neill JP, Finette BA, Bauer MJ, Walker VE. 1999. Genotoxicity of 3′-azido-3′- dideoxythymidine in the human lymphoblastoid cell line, TK6: Relationships between DNA incorpration, mutant frequency, and spectrum of deletion mutations in HPRT. Mutat Res 429:249-259.
48. Thiagalingam S, Foy RL, Cheng KH, Lee HJ, Thiagalingam A, Ponte JF. 2002. Loss of helerozygosity as a predictor to map tumor suppressor genes in cancer: Molecular basis of its occurrence. Curr Opin Oncol 14:65-72.
49. Turker MS, Gage BM, Rose JA, Elroy D, Ponomareva ON, Stambrook PJ, Tischfield JA. 1999. A novel signature mutation for oxidative damage resembles a mutational pattern found commonly in human cancers. Cancer Res 59:1837-1839.
50. UNAIDS. 2005. Global summary of the HIV, AIDS epidemic in 2004. Also available at http://www.unaids.org
51. Vazquez-Padua MA, Starnes MC, Cheng YC. 1990. Incorporation of 3′-azido-3′-deoxythymidine into cellular DNA, its removal in a human leukemic cell line. Cancer Commun 2:55-62.
52. Veal GJ, Back DJ. 1995. Metabolism of Zidovudine. Gen Pharmacol 26:1469-1475.
53. +/- mice treated with zidovudine and lamivudine. Carcinogenesis 23:1427-1432.
54. Von Tungeln LS, Williams LD, Doerge DR, Shaddock JG, McGarrity LJ, Morris SM, Mittelstaedt RA, Heflich RH, Beland FA. 2007. Transplacental drug transfer and frequency of Tk and Hprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine. Environ Mol Mutagen 48:258-269.
55. Wijnhoven SW, Van Sloun PP, Kool HJ, Weeda G, Slater R, Lohman PH, Van Zeeland AA, Vrieling H. 1998. Carcinogen-induced loss of heterozygosity at the Aprt locus in somatic cells of the mouse. Proc Natl Acad Sci USA 95:13759-13764.
56. Wijnhoven SW, Kool HJ, Van Teijlingen CM, Van Zeeland AA, Vrieling H. 2001. Loss of heterozygosity in somatic cells of the mouse. An important step in cancer initiation? Mutat Res 473:23-36.
57. Zhang LS, Honma M, Matsuoka A, Suzuki T, Sofuni T, Hayashi M. 1996. Chromosome painting analysis of spontaneous and methyl methanesulfonate-induced trifluorothymidine-resistant L5178Y cell colonies. Mutat Res 370:181-190.
58. Zhu C, Johansson M, Karlsson A. 2000. Incorporation of nucleoside analogs into nuclear or mitochondrial DNA is determined by the intracellular phosphorylation site. J Biol Chem 275:26727-26731.